Psoriasis
We recommend
Bimekizumab in 3rd Line Biological Treatment After Risankizumab Failure – Case Study
The possibilities of biological therapy for severe forms of psoriasis are very broad today. Achieving remission or reducing disease activity by 90-100% from the baseline state (PASI 90-100) is highly probable, especially when using biological drugs from the IL-17 or IL-23 inhibitor groups. However, individually, patients may exhibit primary or secondary resistance even when using these preparations, necessitating a change in biological treatment. The following case study presents the case of a young man who achieved complete disease remission...
EADV 2023: Nejnovější výsledky bimekizumabu v léčbě ložiskové psoriázy, psoriatické artritidy a axiální spondylartritidy
Na loňském 32. kongresu Evropské dermatovenerologické akademie (EADV) v Berlíně byla prezentována…
Bimekizumab in the Treatment of Psoriasis After Failure of (Not Only) Anti-IL-17A Antibodies – Case Reports
German authors last year described the first 2 cases of patients with psoriasis in whom treatment…
Articles on this topic
Bimekizumab in the treatment of moderate to severe hidradenitis suppurativa – another approved indication for this biological agent
In May, the primary results of the BE HEARD I and II studies evaluating the efficacy and…
Expert Consensus on the Use of Bimekizumab in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
The expert consensus published in February 2024 offers guidance on the use of bimekizumab in…
What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology,…
Mental Health as an Overlooked Topic in Patients with Psoriasis
Psoriasis is an inflammatory, non-infectious disease primarily affecting the skin, and…
AAD 2023: Efficacy of Bimekizumab in the Treatment of Hidradenitis Suppurativa
At the latest annual congress of the American Academy of Dermatology (AAD), held March 17-22,…
Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A…
Safety and Efficacy of Bimekizumab Self-Administration in Psoriasis Patients
Patient adherence to regular administration of biologic therapy is crucial for its…
Efficacy and Safety of Bimekizumab in the Treatment of Moderate to Severe Plaque Psoriasis - BE READY Study Results
The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a…
New Drug in the Biologic Therapy Arsenal for Plaque Psoriasis
Bimekizumab shows promising effects in clinical studies with psoriasis patients. Let's take a…
Bimekizumab – Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?
In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the…
E-courses on this topic
Conferences news
Go to records
Go to records
Go to records
Most read on this topic
- Bimekizumab – Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?
- Mental Health as an Overlooked Topic in Patients with Psoriasis
- Bimekizumab in 3rd Line Biological Treatment After Risankizumab Failure – Case Study
- AAD 2023: Efficacy of Bimekizumab in the Treatment of Hidradenitis Suppurativa
- What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
